Apr 16, 2020
Mayne Pharma Submits New Drug Application for E4/DRSP to the FDA
Jan 27, 2020
Heavy Menstrual Bleeding (HMB) Study 2020: Epidemiology, Trends, Treatment, Unmet Needs, Marketed & Emerging Drugs, Case Reports, Market Outlook to 2028
Jan 22, 2020
Theramex Acquires Commercial Rights for Oral Contraceptive Zoely
Dec 24, 2019
Reversible Contraceptive Devices (General Surgery) - Global Market Analysis and Forecast Model
Dec 04, 2019
Study Finds Key Brain Region Smaller in Birth Control Pill Users
Sep 16, 2019
Exeltis USA, Inc. Announces the Launch of Slynd(TM)(drospirenone) tablets, 4 mg, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24-hour missed pill window and 24/4 Dosing Regimen
Jul 02, 2019
The Future of the Intrauterine Devices (IUD) Market by Product, End-use and Region (2019-2024)
Jun 06, 2019
Exeltis USA, Inc. Announces the Approval of Slynd(TM), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window
Jun 04, 2019
Global contraceptive pills market was valued at $ 6 billion in 2018 expected to witness growth at a CAGR of 6.6%, to reach $ 8.8 billion by 2024
Feb 08, 2019
Hormonal Contraceptive Market to Touch US$ 30,930.5 Million by 2026, Says TMR
Dec 19, 2018
Celmatix Biosciences Launches Search for Next-Generation Oral Contraceptives
Dec 17, 2018
Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
Nov 29, 2018
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis
Nov 02, 2018
Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM® 1/35 and two lots of ORTHO-NOVUM® 7/7/7 Due to Incorrect Veridate® Dispenser Instructions
Oct 11, 2018
Contraceptives Market is Anticipated to Reach US$ 37,242.7 Million by 2025, Says TMR
Sep 26, 2018
Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora®
Sep 06, 2018
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Aug 21, 2018
Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application
Aug 20, 2018
Medicines360 and Direct Relief Partner to Expand Access for U.S. Women
Aug 10, 2018
FDA Approves the First One-Year Contraceptive Fully under a Woman's Control